EICHOR
● Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Condition: Alzheimer Disease · Alzheimer Disease Due to P. Gingivalis · Sponsor: Lighthouse Pharmaceuticals, Inc.
About this study
This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P. gingivalis bacterium, to potentially help to halt or slow down the progression of AD and its symptoms. A saliva test will be done to determine P. gingivalis infection. Tests for AD include standard questionnaires such as MMSE and a blood test for pTau217. Treatment will be blinded, meaning the participant and the doctor will not know if the participant is receiving LHP588 or placebo. The total time for participation in the study may be up to 64 weeks. This includes a screening period (to ensure the participant is suitable for the study and the study is suitable for the participant) of up to 12 weeks, a treatment period of up to 48 weeks, and a safety follow-up period of 4 weeks after the last dose of the study drug to check the participant's overall health. Treatment is a once-a-day capsule. Caregiver participation is required. The study requires the participant to visit the study center (with the caregiver) at least 20 times within 64 weeks (this does not include any unplanned visits that may be recommended by the study doctor). In addition, the study doctor or clinic staff will contact the participant via phone at least 1 time.
This description comes directly from the study's public registry record.
Talk to the study team
Joanna Bolger · 858-248-5124 · jbolger@lighthousepharma.com
Always discuss trial participation with your own doctor first.
Locations (40)
| Banner Alzheimer's Institute | Phoenix, Arizona, United States | Recruiting |
| Barrow Neurological Institute | Phoenix, Arizona, United States | Recruiting |
| Clinical Endpoints | Scottsdale, Arizona, United States | Recruiting |
| Oakland Clinical Research | Oakland, California, United States | Recruiting |
| ATP Clinical Research, Inc. | Orange, California, United States | Recruiting |
| Riverside Clinical Research | Riverside, California, United States | Recruiting |
| CenExel Sherman Oaks | Sherman Oaks, California, United States | Recruiting |
| CenExel Denver, CO | Englewood, Colorado, United States | Recruiting |
| JEM Research Institute | Atlantis, Florida, United States | Recruiting |
| Brain Matters Research | Delray Beach, Florida, United States | Recruiting |
| Neuropsychiatric Research Center of Southwest Florida | Fort Myers, Florida, United States | Recruiting |
| Conquest Research - Lake Nona | Orlando, Florida, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06847321